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1. Introduction 
Senescence-accelerated mouse (SAM) lines serve as models of aging and age-associated 
diseases. The SAMP8 strain has a shortened life span and early-onset manifestations of 
senescence with characteristic pathological features observed in elderly humans, including 
deficits in learning and memory. In brains of SAMP8 mice, the processing of amyloid 
precursor protein (APP) is altered, resulting in excess production and accumulation of 
amyloid-┚ peptide (A┚), tau is hyper-phosphorylated, and oxidative stress is increased. 
These phenotypic abnormalities are quite reminiscent of the findings in human brains with 
Alzheimer’s disease (AD). Mechanistically, metabolic pathways that are responsible for the 
generation of reactive oxygen species (ROS) are increased, while antioxidant systems are 
reduced in activity in the cerebral cortex of aged SAMP8 mice. Besides these structural and 
metabolic alterations, brains of aged SAMP8 mice exhibit neurochemical abnormalities such 
as altered signaling through G protein-coupled receptors for 5-hydroxytryptamine, 
acetylcholine, adenosine, dopamine, melatonin, glutamate and GABA, ion channel 
receptors, and nuclear hormone receptors (e.g. for all-trans-retinoic acid, cortisol or 
estradiol). Consequences include alterations in the levels of neurotransmitters, receptor 
numbers, receptor binding affinity, and second messengers. Of note is that in AD, G protein-
coupled receptors and/or their corresponding signaling pathways are often impaired. 
Together, the observations in aged SAMP8 mouse brains provide convincing evidence that 
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this model serves as an excellent research tool for studying AD pathogenesis and strategies 
for treatment. Additionally, many of the pathological and neurochemical abnormalities in 
SAMP8 mice are linked to altered expression of genes that are integrally related to processes 
such as neuroprotection, signal transduction, protein folding/degradation, intracellular 
transport and immune response. Several studies have already utilized pharmacological or 
dietary measures to restore cognitive function and enhance neuroprotection in aged SAMP8 
mice, suggesting that these approaches may have applications in the treatment of AD. This 
review compiles available data concerning the signaling pathways that are altered in 
SAMP8 mice, and compares the effects to known abnormalities in AD brains. 
2. Senescence-Accelerated Mouse model hallmarks: the interest in SAMP8 
strain  
The senescence-accelerated mouse (SAM) model of accelerated senescence was originally 
established by Dr. Takeda at the University of Kyoto through phenotypic selection from a 
common genetic pool of the AKR/J strain. After continuous sister-brother mating to 
maintain the line under conventional conditions, some littermates were found to differ from 
the original offspring. This distinct subset of mice exhibited an unusual phenotype 
characterized by early-age onset senility and shortened lifespan. Five litters with this new 
phenotype were selected as progenitors of the senescence-accelerated-prone mice (SAMP), 
while 3 litters with normal ageing were selected as progenitors of the senescence-
accelerated-resistant mice (SAMR) (Takeda et al., 1981). Fourteen SAMP and four SAMR 
litters were produced from the original breeding pairs (Takeda, 1999). In the SAMP mice, 
the first signs of premature aging were hair loss, reduced physical activity, ophthalmic 
disorders, and shortened lifespan (mean lifespan of 9.7 months versus 16.3 months for 
SAMR mice) (Takeda et al., 1994). These and other characteristic features of SAMP mice are 
summarized in Table 1. 
The use of experimental models to study the beginning and the course of senescence and, in 
a pharmacological approach, to design drugs capable of delaying this process has been 
widely accepted. Some examples of these experimental approaches are the development of 
genetically modified organisms, which overexpress genes related to aging, chemical increase 
of free radicals, viral inoculation, pharmacological interference with some nerve and 
endocrine functions, and stress induction, among others. These are very useful approaches 
but present some disadvantages which are not within the scope of this chapter to describe. 
Moreover, in recent years there has been brought to light a need for improved animal 
models as a critical barrier in the study of several neurodegenerative disorders. In the 
particular case of AD study, a direct consequence of the knowledge of AD etiology is that 
scientists are not able to design an animal model that fully resembles AD pathology. 
Furthermore, time is not on our side; it has been estimated that nowadays AD affects at least 
30 million people around the world, death occurs within 10 years of diagnosis (Lee & 
Chodosh, 2009), and predictions are not encouraging at all. In the year 2050 the number of 
ageing people will be on the order of two billion people (WHO data and statistics), most of 
them in developed countries, which would exponentially increase the number of 
Alzheimer’s patients. Nowadays, the available animal models of AD are restricted to the 
overexpression of genes with specific mutations associated with early-onset familial AD, 
which only represents ≈5% of AD cases— considered by many researchers, although useful, 
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to be models with poor clinical relevance and limited predictive value. The use of SAM 
strains has allowed researchers to pursue a more biological approach to study senescence 
processes. As may be observed in the central column of Table 1, the main feature of all SAM 
strains is accelerated senescence, which is the reason why they are a widely used animal 
model to study geriatric disorders. It is necessary to establish the difference between 
accelerated senescence and pathologic senescence. The former is the biological phenomenon 
observed in living organisms as time goes by. In this case, the observer only reports a faster 
course of events when compared to physiologic senescence (which is also convenient from a 
technical point of view). The latter refers to a pathological phenomenon that alters aging 
process by interacting with biological processes, inducing premature senescence. 
 
Strain Characteristics Geriatric disorders 
SAMP1 Senile amyloidosis 
Impaired immune system 
Impaired auditory system 
Retinal atrophy 




Atrophy of the retina 
Senile cataracts 
Senile lung 
SAMP2 Senile amyloidosis 
Impaired immune system 
Senile cataracts 
Senile lung 
SAMP3 Degenerative arthrosis Degenerative joint disease 
SAMP6 Senile osteoporosis Senile osteoporosis 
SAMP7 Senile amyloidosis 
Thymoma 
 
SAMP8 Age-related learning and memory 
deficits 
Anxiety 
Impaired immune system 
Age-dependent deposition of amyloid 
┚-peptide 
Deficits in learning and memory 
Emotional disturbances 
Abnormal circadian rhythm 
Damage to the blood-brain 
barrier 
SAMP9 Age-related cataracts Senile amyloidosis 
SAMP10 Brain atrophy 
Age-related learning and memory 
deficits 
Age-related depression 
Deficits in learning and memory 
Forebrain atrophy 
Abnormal circadian rhythm 
SAMP11 Age-relating thickening of tunic media 
of thoracic aorta 
Senile amyloidosis 
Contracted kidney 
Diffuse medial thickening of the 
aorta 
Table 1. Summary of the main features of different strains of SAMP model. From Butterfield 
& Poon, 2005 and Chiba et al., 2009. 
During the past century, a considerable number of theories have been proposed to explain 
the nature of aging from the different points of view which are involved in it: molecular, 
cellular, tissue level, etc. This has made it a difficult task to achieve. Nowadays, the scientific 
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community is still debating which of these theories is the one to explain all the changes 
reported during aging, but although there is not a universally accepted theory of aging, the 
free radical theory (Harman, 1956) seems to be the one with the most adherents. This theory 
postulates that changes observed during aging are due to the direct action of free radicals, 
generated during cellular metabolism, over biomolecules. Hence, chemical oxidation of 
proteins, DNA, lipid membranes and other biomolecules induced by reactive oxygen 
species (ROS) leads to cellular dysfunction and aging in humans and animals. Furthermore, 
ROS damage has been described as the first pathologic event that occurs in the brain of AD 
patients (Nunomura et al., 2001) and in SAMP8 strain (Pallas et al., 2008). Following these 
facts, the SAMP8 strain seems to be a valid animal model for the study of AD as the 
molecular mechanism that generates age-related impairments (even if it is not the only one, 
Zhu et al., 2007) in both senescent mouse and AD patients appears to be the same. 
SAMP8 strain has been extensively studied by comparing aged SAMP8 mice with aged 
SAMR1 mice, and also aged SAMP8 mice with young SAMP8 mice. In both cases, 
neuropathological, neurochemical, and, especially, behavioral/cognitive abnormalities 
found in aged SAMP8 mice are similar to the deficits observed in AD patients and in some 
genetically modified animals. Moreover, the chronology of AD symptoms and appearance 
of pathology are closer to abnormalities described in SAMP8 strain than to what is reported 
in other genetically modified animals (Pallas et al., 2008). Recently, SAMP8 strain has caught 
the attention of several investigators, owing to its unique characteristics, with special focus 
in their use as neurodegenerative models (Pallas et al., 2008; Takeda, 2009). This strain 
spontaneously develops a pathologic phenotype characterized by age-related disorders, 
such as learning and memory deficits, mood disorders, such as reduced anxiety-like 
behavior and depressive behavior, and abnormality of circadian rhythm. In addition, when 
APP cDNA from SAMP8 strain was sequenced, familial AD mutations were not found 
(Kumar et al., 2001), suggesting that the age-related disorder reported in this strain was 
probably not following the same pathways as observed in familial AD. Furthermore, A┚ 
levels found in SAMP8 mice seem to be closer to those observed in AD patients than what 
has been reported in genetically modified mice (Rosenberg, 2000). This is, precisely, 
SAMP8’s main characteristic: the age-related phenotype is developed spontaneously and in 
almost the same order as reported in human beings. That is the reason why this animal 
model is a high value-added model; neurodegenerative observations reported in this model 
are not due to the introduction or the deletion of a gene(s) in an animal model but are 
directly induced by physiological processes. 
Age-related deficits in SAMP8 strain have been known for a long time. Since their first 
description by Dr. Takeda, several laboratories have associated behavioral changes to age-
related cognitive impairment. However, Dr. Takeda’s laboratory was the first to globally 
describe age-related cognitive deficits in SAMP8 mice compared to SAMR1 age-matched 
controls (Miyamoto et al., 1986). They reported an age-associated increase in spontaneous 
motor activity, impairment in the acquisition of passive avoidance response at 2 months of 
age, and impairment in the acquisition of active avoidance response at 12 months of age. 
Alternative paradigms designed to test other behavioral tasks, such as spatial memory 
acquisition, are particularly useful to study age-related deficits, as memory and learning 
deficiencies are directly dependent on hippocampal function. These experiments, such as 
multiple T-maze and Morris water maze, showed an age-related impairment of spatial 
memory acquisition in 2-month-old SAMP8 mice. Nevertheless, these results turned 
controversial as other groups found different onset times for SAMP8 age-related 
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impairments in learning and memory depending on the test used (reviewed in Flood & 
Morley, 1998). Taken together, all these studies suggest that learning and memory tasks are 
impaired in SAMP8 mice at early age which will be detected at one or another age 
depending on the specific aspect of learning and memory measured by the experimental test 
used. These age-related cognitive deficits found at an early age in SAMP8 mice have been 
used by researchers to connect treatments focused on neuropathological abnormalities with 
improvements in physiologic functions such as learning and memory acquisition. The most 
relevant pathological defects found in SAMP8 mice will be discussed in this section. 
In the section bellow, we will consider the main features that are known to occur early in the 
pathogenesis of AD and which the SAMP8 strain exhibits, such as increased oxidative stress, 
amyloid-┚ alterations and tau phosphorylation. Although not commented upon here, other 
features that have been described in AD pathogenesis have been also found in SAMP8 
model as: gliosis (Lu et al., 2009), protein alterations in neurons and astrocytes (Diez-Vives 
et al., 2009), lower hippocampal PKC activity (Hung et al., 2001), and altered protein 
expression in the olfactory system (Poon et al., 2005c). 
3. Pathological findings in SAMP8 mice 
The unique characteristics of SAMP8 mice are not new, but recently this strain has drawn 
the attention of researchers 1 in the area of gerontological study of dementias as a result of 
its exclusive development of learning and memory deficits with age (Flood & Morley, 1998) 
and as a consequence of the clinical relevance obtained employing other commonly used 
AD models. In this section, we will summarize recent findings related to pathological data 
obtained from the SAMP8 strain that are also common in the pathophysiology of AD: 
damage induced by oxidative stress, A┚ deposition and hyperphosphorylation of tau 
protein. 
3.1 Oxidative stress 
Free radical-mediated damage to neuronal membrane components has been implicated in 
the etiology of Alzheimer's disease (AD) and aging; in fact, as has been previously noted, 
one of the earliest events to occur in AD is oxidative stress (Nunomura et al., 2001). 
Furthermore, loss of functional enzyme activity during aging had previously been 
associated with oxidative modification of enzymes (Oliver et al., 1987). Early studies 
focusing on the oxidative stress level of SAMP8 mice detected elevated levels of lipid 
peroxide and protein carbonyl in cerebral cortex of SAMP8 mice as young as 4 to 8 weeks 
old, compared to those of SAMR1 controls (Sato et al., 1996b). After this discovery, this 
group also confirmed that the oxidative events could be triggered by the loss of activity of 
anti-oxidative enzymes, such as catalase, and/or by the increase of activity of pro-oxidative 
enzymes, such as acyl-CoA oxidase (Sato et al., 1996a). These were the first reports that 
supported the fact that oxidative stress is one of the earliest events related to AD pathology 
that happen in the SAMP8 strain, and they lead to later papers that studied oxidative stress 
as a loss of functionality of anti-oxidative enzymes or as an increase in functionality of pro-
oxidative enzymes. 
                                                                 
1 Searching for “senescence-accelerated mouse” in PubMed database reported 401 citations on March, 25 2011. 
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Other authors have complemented these studies using more powerful approaches, such as 
proteomics, to study the level of carboxylation of proteins in the SAMP8 strain. Therefore, 
higher protein oxidation and lipid peroxidation reported by Sato et al. were confirmed in 12-
month-old SAMP8 mice (Poon et al., 2004a). Those oxidative stress markers were reduced 
not only when SAMP8 mice were treated with antioxidants, such as ┙-lipoic acid (Poon et 
al., 2005b), as would be expected, but also when antisense therapy directed to decrease APP 
expression was carried out (Poon et al., 2004b, 2005a). Both approaches are capable of 
reversing cognitive deficits in 12-month-old SAMP8 mice. Furthermore, a complete 
proteomics study including about 1700 proteins was carried out in SAMP8 and SAMR1 mice 
(Zhu et al., 2011). In this report there was found to be a group of proteins which were 
expressed in an age-dependent way and, interestingly, some of them had previously been 
found to be expressed in AD patients. One of these, Cu/Zn superoxide dismutase (De Leo et 
al., 1998), will be commented upon later in this chapter. Taken together, these reports related 
to oxidative stress have not only provided understanding of the mechanisms underlying 
memory and learning deficits but have also suggested potential therapies to counteract age-
related dementia. Therefore, it has been demonstrated for the SAMP8 strain that age-related 
dementia observed in these animals is ROS-dependent, as the treatment with antioxidants 
improved learning and memory ability and reduced A┚ deposition (Shih et al., 2010). 
Several studies have been carried out in the SAMP8 strain focused on physiologic enzymes 
with antioxidant properties that counteract ROS produced by oxidative metabolism, or on 
enzymes with pro-oxidant properties that support ROS production. The first of these was 
carried out a long time ago when SAM nomenclature had not yet been established. In this 
study, there was reported to be elevated activity of monoamine oxidase B (MAO-B) and 
decreased activity of superoxide dismutase (SOD) in SAM-P mice versus SAM-R mice 
(Nomura et al., 1989). After that, more detailed studies were performed specifically in the 
SAMP8 strain where there was reported to be a decrease in manganese superoxide 
dismutase (Mn-SOD) activity in 10-month-old SAMP8 mice (Kurokawa et al., 2001), and an 
age-related decrease in Cu/Zn superoxide dismutase (Cu/Zn-SOD) expression in 5 to 15-
month-old SAMP8 mice (Zhu et al., 2011), as well as in activity of glutathione peroxidase in 
12-month-old SAMP8 mice (Okatani et al., 2002). Furthermore, glutathione reductase, 
glutathione peroxidase and catalase activities were lower in 5-month-old SAMP8 mice than 
in aged-matched SAMR1 mice (Sureda et al., 2006).  
Another family of enzymes involved in ROS damage is nitric oxide synthases (NOS) 
composed of three isozymes. Nitric oxide (NO) is a signaling molecule widely distributed in 
the nervous system whose increase has been related to a variety of neurodegenerative 
pathologies such as AD (Steinert et al., 2010). In SAMP8 mice an age-related increase of NOS 
activity has been reported which can be reduced by natural antioxidants (Inada et al., 1996). 
This age-related increase in NOS activity was not due to an increase in mRNA or protein 
levels (Ali et al., 2009). Although it has been previously reported that A┚ antisense treatment 
reduced oxidative stress markers (Poon et al., 2004b), recent studies suggest that regulation 
of the NOS family is complex, as A┚ antisense or antibody treatment further increased NOS 
activity, with an increase in inducible NOS (iNOS), and reduced neuronal NOS (nNOS). No 
changes were reported in endothelial NOS (eNOS) (Ali et al., 2009). 
A summary of the reported variations in enzymatic activity of anti and pro-oxidant enzymes 
in the SAMP8 strain is presented in Table 2. 
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Anti-oxidative enzymes 
(decreased oxidative stress) 
Pro-oxidative enzymes 
(increased oxidative stress) 
Catalase ↓ Acyl-CoA oxidase ↑ 
Manganese superoxide dismutase ↓ Monoamine oxidase B ↑ 
Cu/Zn superoxide dismutase ↓ NOS ↑ 
Glutathione peroxidase ↓  
Glutathione reductase ↓  
Table 2. Summary of the variations reported in enzymes related to oxidative stress in the 
SAMP8 strain. 
Some antioxidants, such as melatonin, have been used in SAMP8 mice to counteract 
oxidative damage. The effect of melatonin treatment on the activity of AD-related kinases 
has been described (Gutierrez-Cuesta et al., 2007). In addition, melatonin-treated SAMP8 
mice reported elevated levels of activity of glutathione peroxidase, an anti-oxidant 
enzyme, improving indexes of lipid peroxidation and oxidative stress by a combination of 
melatonin scavenger activity and its ability to stimulate anti-oxidant enzymes (Okatani et 
al., 2002). Furthermore, as there is clear evidence of the relationship between oxidative 
stress and age-related dementias in SAMP8 strain, these mice have also been used to test 
the effects of some natural antioxidants in the diet. Natural antioxidants derived from 
plants, such as rose-flower extract, have been tested as antioxidant compounds in the 
SAMP8 strain. In this case, it was demonstrated that antioxidant treatment increased 
activity and expression of the anti-oxidant enzymes catalase and glutathione peroxidase, 
decreasing lipid peroxidation and therefore extending the lifespan of SAMP8 (Ng et al., 
2005). The antioxidant effects of other plant extracts, such as Toona sinensis Roemor, have 
been also tested in the SAMP8 strain. The results obtained demonstrated that dietary 
supplemented animals presented decreased A┚ deposition and lower levels of antioxidant 
markers as well as higher levels of anti-oxidant enzymes, such as SOD, catalase and 
glutathione peroxidase (Liao et al., 2006). Recently, icariin, a flavonoid extracted from 
several plant species, was shown to improve age-related deficits in SAMP8 mice by 
decreasing NO levels and NOS activity, and by increasing glutathione peroxidase and 
SOD activities (He et al., 2010). Finally, the administration of lotus seedpod 
proanthocyanidins to SAMP8 mice decreased NO levels and lowered NOS activity while 
increasing glutathione peroxidase and SOD activity, which correlates whit an 
improvement in SAMP8 cognitive deficits (Gong et al., 2008) 
Nevertheless, the literature related to oxidative stress in SAMP8 strain is not always 
conclusive. For example while Okatani et al. did not find age-related changes in SOD, either 
in SAMP8 or in SAMR1 strain (Okatani et al., 2002), Alvarez-Garcia et al. did not observe 
any age-related differences in activity of catalase and glutathione reductase, while they did 
in SOD (Alvarez-Garcia et al., 2006). Finally, Sureda et al. found decreased activity of 
glutathione reductase, glutathione peroxidase and catalase in SAMP8 mice (Sureda et al., 
2006). In addition, other systems might also participate in brain oxidative stress processes. 
Recent studies have demonstrated that, as in AD brain, peroxide detoxification by astrocytes 
could play a role in age-related cognitive deficits. Astrocytes derived from SAMP8 mice 
were more susceptible to H2O2 induced damage than those derived from SAMR1 mice. 
Decreased peroxide detoxification was seen in SAMP8 mice (Lu et al., 2008). Taken together, 
these results remind us that there is still a long way to go before we completely understand 
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the role of oxidative stress in SAMP8 age-related cognitive deficits and, by extension, in AD 
pathology. 
3.2 Amyloid-β deposition 
Senile plaques are one of the hallmarks of AD and have become one of the main hypotheses 
for the development of this disease (Selkoe, 2000). This hypothesis is based on the fact that 
familial AD (≈5% of AD cases) may be caused by mutations in the amyloid-┚ precursor 
protein (APP) or by mutations in genes that participate in amyloid-┚ cleavage (presenilins-
1/2). According to this hypothesis, the increase in A┚ peptide, which would result in an 
increase in the number of senile plaques, is the main factor that triggers the rest of the 
clinical and histopathological features reported in AD. Although this hypothesis has not 
been refuted, it has not been demonstrated, despite the vast knowledge acquired from 
models and clinical studies, and even most current reviews on this topic continue to include 
the words “hypothesis” or “speculation” (Marchesi, 2011). 
Although the SAMP8 strain has been proposed as a model of AD, the chronology of 
appearance of A┚ deposits has been controversial for a long time. Furthermore, there was 
one main difference between these deposits and the ones found in humans: SAMP8 A┚ 
deposits were not stained using Congo red and Thioflavin S (Takemura et al., 1993), a classic 
method used to stain amyloid plaques (Kelenyi, 1967). This main difference has led some 
researchers to incorrectly consider the age-related dementia described in SAMP8 mice as 
independent of amyloid plaque deposition (Ashe & Zahs, 2010). In one of the first studies of 
A┚ deposition in SAMP8 strain, the authors Takemura et al. proposed that little differences 
in the primary structure of APP or in the processing enzymes could lead to different 
processed proteins that might be responsible for their different polymerization into the ┚-
pleated sheet. Although possible, this explanation seems improbable since it has been 
demonstrated that SAMP8 APP protein shows high similarity to that of other species (99.2% 
homologous with that of mouse and rat (Kumar et al., 2001)). In addition, since its discovery 
in 1967, the staining method based on fluorophores, such as Congo red and Thioflavin S, has 
been modified in order to increase the resulting resolution (Sun et al., 2002). 
Nevertheless, A┚ deposits in SAMP8 strain have been detected in AD-affected regions 
(including the hippocampus, medial septum, cerebral cortex and cerebellum) using a wide 
variety of antiserum, although until a few years ago the date of appearance of A┚ deposits 
was open to question. One of the first studies to demonstrate the appearance of amyloid 
plaques in young SAMP8 mice was published in 2006 (Liao et al., 2006), but it was not until 
2010 that a complete study was carried out. In this research, Del Valle et al. performed a 
time course of A┚ deposition in SAMP8 strain, demonstrating that amyloid plaques could be 
observed in the hippocampus of 6-month-old SAMP8 mice and that they increased with age, 
while 15 months was needed to observe them in control SAMR1 mice (Del Valle et al., 2010). 
As well as immunodetection, quantitative expression studies of AD-related genes were 
carried out. All this research points to an increase in A┚ levels in the SAMP8 strain. In this 
sense, an age-related increase of expression of APP gene in SAMP8 hippocampus has been 
detected which correlated with an age-related increase in APP protein levels (Morley et al., 
2000; Poon et al., 2004a). In agreement with these findings, variations in the expression of 
other genes related to AD pathology have also been reported. In this sense, there have been 
studies of the expression of presenilin-1 (PS1) and presenilin-2 (PS2), two proteins that are 
included in the ┛-secretase complex whose mutations give rise to an increase in 
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amyloidogenic cuts of APP observed in familial AD. In the SAMP8 strain an increase in the 
gene expression of both PS1 and PS2 has been reported (Wei et al., 1999; Kumar et al., 2009) 
which may be one of the causes of increased processing of APP that leads to A┚ 
accumulation. The expression of another familial AD marker, apolipoprotein E (ApoE), was 
also studied in the hippocampus of the SAMP8 strain (Wei et al., 1999). This biomarker was 
less expressed in SAMP8 mice compared to the SAMR1 strain. In contrast, ApoE allele 4 
expression is associated with increased susceptibility to AD. Although, the connection 
between AD and ApoE is not clear, some researchers postulate that ApoE could be the link 
between A┚ deposition and pathological alterations of the cerebral microvasculature in AD 
(Marchesi, 2011). Apolipoprotein A-II (ApoAII) is the precursor protein that induces mouse 
senile amyloidosis, a form of amyloidosis in which the severity of A┚ deposition increases 
with age. This has also been the focus of research in SAMP8 strain which expresses type A 
ApoAII, considered as moderately amyloidogenic (Higuchi et al., 1991). This finding made 
the SAMP8 strain an appropriate model system for the study of the mechanism(s) of age-
related amyloid fibril formation. In conclusion, all the foregoing research suggests that every 
one of these findings could contribute to the age-related A┚ accumulation described in the 
SAMP8 strain. 
In addition to all the data already considered, there are other factors that contribute to A┚ 
accumulation. Among these is the A┚ peptide rate of efflux from the brain to blood. There 
are some hypotheses concerning how this peptide could be transported across the blood 
brain barrier which will not be discussed here. What is clear, however, is that the higher the 
efflux rate of A┚ is, the less A┚ remains inside the central nervous system where it may 
accumulate. This phenomenon was studied by Banks et al., using radioactive labeled A┚ 
which was centrally administered to SAMP8 mice. This group demonstrated that A┚ efflux 
was impaired in SAMP8 mice, suggesting that A┚-impaired efflux could be an early 
contributor to A┚ deposition in the SAMP8 strain (Banks et al., 2003). 
As noted above, if the hypothesis that A┚ deposition is responsible for the 
cognitive/behavioral deficits observed in SAMP8 strain holds, then when A┚ accumulation 
is inhibited, independently of the technique employed, the reported cognitive and 
behavioral deficits should improve. This hypothesis is correct for APP inhibition in SAMP8 
strain and has been validated by several reports. Some of these have been commented upon 
earlier in this chapter but the original work in which downregulation of APP was achieved 
using a specific oligonucleotide was performed by Kumar et al. (Kumar et al., 2000). After 
this report, other authors demonstrated that APP expression could be decreased using 
antisense APP oligonucleotides (Poon et al., 2004b), improving learning and reversing 
memory deficits. Recently, a new strategy, employing micro ribonucleic acids (miRNAs), 
which are post-transcriptional regulators of APP in SAMP8 mice and show different 
expression patterns in SAMP8 and SAMR1 mice, has been proposed (Liu et al., 2010b). 
These authors hold that as miRNAs (miR-16, miR-144, miR-195, and miR-383) negatively 
regulate APP expression in SAMP8 strain, the use of these miRNAs could help to improve 
cognitive deficits in the SAMP8 strain, although this hypothesis has not been tested yet. 
Furthermore, A┚ immunotherapy strategies were employed as well using A┚-directed 
antibodies, injected intracerebroventricularly (Morley et al., 2002) or intraperitoneally 
(Zhang et al., 2011), with recovery in cognitive deficits in reported in the SAMP8 strain. 
Although A┚ accumulation is associated with cognitive impairment, there are some animal 
models of AD whose age-related brain disorders are not related to amyloid plaques but 
rather to abnormal APP metabolism that could accelerate age-related brain disorders 
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independently of A┚ deposition (Ashe & Zahs, 2010). As can be deduced from all the 
evidence described here, this is not the case with the SAMP8 strain. In addition, there was a 
study recently carried out using a monoclonal antibody against A┚ oligomers on SAMP8 
mice which makes it increasingly evident that the age-related deficits observed in SAMP8 
strain are A┚ deposition-dependent. In this study, the administration of this specific 
antibody to SAMP8 mice improved learning and memory tasks and decreased A┚ oligomers 
and phospho-tau levels (Zhang et al., 2011). 
3.3 Hyperphosphorylation of tau 
The presence of neurofibrillary tangles, consisting of hyperphosphorylated tau protein, is 
another hallmark of AD, although formation of neurofibrillary tangles is considered a 
consequence of A┚ accumulation (Hardy & Selkoe, 2002). Tau is a highly soluble protein 
which is implicated in microtubule assembly and stabilization whose 6 known cerebral 
isoforms are translated from a single gene by alternative splicing. Although tau mutations 
have been involved in a variety of neurodegenerative disorders named familial tauopathies 
(Goedert et al., 1998), tau is not mutated in AD. Different tau functions are controlled by 
site-specific phosphorylation which affects microtubule binding. While kinase-mediated 
phosphorylation inhibits microtubule binding, phosphatase-mediated dephosphorylation 
restores microtubule binding. In AD pathology, aberrant tau hyperphosphorylation induces 
microtubule instability and promotes a toxic effect on neurofibrillary tangles surrounding 
neurons (Johnson & Stoothoff, 2004). Therefore, if the SAMP8 strain is a valid animal model 
for the study of AD, the pathology induced by tau phosphorylation should be similar in AD 
and in SAMP8 mice. 
In contrast to A┚ accumulation, total tau quantity is not a critical factor in toxicity, as is 
kinase-mediated phosphorylation. Consequently, an increase in phosphorylated tau in 
SAMP8 (cortex, striatum and hippocampus, and to a lesser extent in cerebellum) has been 
detected compared with SAMR1, whilst levels of tau protein were maintained overall in the 
different areas (Canudas et al., 2005). Furthermore, elevated levels of phosphorylated tau 
protein were found in SAMP8 strain at an early age, in 5-month-old mice (Alvarez-Garcia et 
al., 2006), indicating that tau phosphorylation is an early event in the SAMP8 strain. Thus, 
the kinase(s) responsible(s) for the phosphorylation of tau protein in the SAMP8 strain 
needed to be studied in detail. Two of the serine/threonine kinases which phosphorylate 
human tau protein are cyclin-dependent kinase 5 (CDK5) and glycogen synthase kinase 3 
(GSK3). When they were studied in detail, an elevated activity of CDK5 accompanied by an 
increase in expression was detected in cortex, striatum, hippocampus and, a lesser extent, in 
cerebellum (Canudas et al., 2005). However, GSK3┚ expression and activity were not altered 
in SAMP8 mice (Canudas et al., 2005). Yet chronic melatonin treatment in SAMP8 mice 
diminished tau hyperphosphorylation, reducing CDK5 and GSK3┚ activation and 
suggesting that these kinases and their downstream pathways participate in tau hyper-
phosphorylation in SAMP8 mice (Gutierrez-Cuesta et al., 2007). 
Besides the relationship between tau protein and AD-related kinases, a relationship that 
links oxidative stress and tau phosphorylation has also been established. We noted earlier 
the work of Gutierrez-Cuesta et al., which links chronic antioxidant treatment with reduced 
tau phosphorylation, probably due to a reduction in CDK5/GSK3┚ activation, in SAMP8 
mice. This relationship is attested by the abundant bibliography that supports the 
antioxidant properties of lithium. Lithium treatment in SAMP8 mice decreased 
CDK5/GSK3┚ activation, reducing tau phosphorylation and providing neuroprotection to 
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SAMP8 mice (Tajes et al., 2008). However, to date GSK3 has not been seen to be involved in 
the antioxidant properties of lithium (Camins et al., 2009). All the data corroborates a 
chronology of appearance of AD-like pathology in the SAMP8 strain: as oxidative stress is 
considered an early event in AD, the use of antioxidants should improve subsequent events 
in this pathology. 
Recently, it has been postulated that elevation of endogenous formaldehyde levels may be 
related to the pathogenic processes of neurodegenerative diseases. From this, it has been 
demonstrated that some aldehydes, directly related to lipid peroxidation, are not only able 
to enhance amyloid plaque formation (Chen et al., 2006), but also to induce misfolding of 
tau protein and formation of globular amyloid-like aggregates (Nie et al., 2007). Thus, in 
addition to all the available research pointing to SAMP8 as an appropriate model for the 
study of age-related disorders, it has been recently described that formaldehyde levels are 
significantly increased in the SAMP8 strain (Tong et al., 2011), which suggests that 
endogenous formaldehyde is related to aging and that SAMP8 strain could be a suitable 
system for the study of these neurotoxic aggregates that could play a role in the induction of 
tauopathies. 
4. Neurochemical changes in SAMP8 mice: GPCR mediated pathways 
G protein-coupled receptors (GPCRs) are a large superfamily of membrane-bound signaling 
proteins that are involved in the regulation of a wide range of physiological functions and 
which constitute the most common target for therapeutic intervention (Ma & Zemmel, 2002).  
Visual, olfactory and taste sensation, intermediary metabolism, cell growth, differentiation 
and many other phenomena are all influenced by GPCR signals (Luttrell et al., 2008). GPCR 
had been viewed as a simple on-off switch that used a single class of effector molecule: the 
heterotrimeric G proteins. However, converging lines of evidence demonstrate the existence 
of G protein-independent signal transduction and its unique biochemical and physiological 
effects (Rajagopal et al., 2010). This increasing complexity of molecular mechanisms 
responsible for GPCR signaling and its regulation, through interplay of positive and 
negative regulatory events that amplify the effect of a hormone binding the receptor or that 
dampen cellular responsiveness, should be tackled as a very promising field to develop new 
therapeutic approaches. Many G protein-coupled receptors and/or their corresponding 
signaling pathways, such as cholinergic, glutamatergic, serotonergic, adrenergic and 
peptidergic neurotransmitter systems, are deregulated in brain from AD cases. This 
deregulation could be responsible for an altered sequential cleavage of APP by the ┙-, ┚-and 
┛-secretases, which are regulated by GPCRs, and the determination of the extent of amyloid-
┚ peptide generation. In turn, amyloid-┚ can directly or indirectly affect GPCR function (for 
a review see Thathiah & De Strooper, 2011). Different neurochemical changes have also been 
found in the SAMP8 brain, including modifications in signal transduction pathways 
mediated by G protein-coupled receptors, ion channel receptors and nuclear hormone 
receptors. These changes have been reported at different levels (e.g. neurotransmitter 
concentration, receptor number and/or affinity, second messenger generation). Several 
GPCRs have been analyzed in the SAM model. However, many available data deal with the 
effects on learning and memory deficits in SAMP8 mice due to the administration of 
different ligands with agonist activity on these receptors. In contrast, very few reports have 
tried to analyze the possible modulation of the receptor itself (i.e., quantity, affinity, 
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regulation, etc.). Available data on different GPCR pathways analyzed in AD and the 
SAMP8 model are summarized in Table 3. 
4.1 Serotonin receptors 
The 5-hydroxytryptamine (5-HT; serotonin) receptors belong to both the G protein-coupled 
and ligand-gated ion channel superfamilies. These have been divided into seven distinct 
families, or classes, according to structural diversity and the preferred effector mechanism. 
Some of these classes comprise multiple receptors, which share similar structural and 
effector properties while displaying very different operational profiles (Barnes & Sharp, 
1999). The serotonergic system has been implicatred in learning and memory (Reis et al., 
2009). A possible age-related change in serotonin (5-HT) receptor antagonist dose–response 
curves was analyzed in SAMP8 mice using a retention test on a T-maze footshock avoidance 
apparatus (Flood et al., 1996, 1998).  5-HT1 and 5-HT2 receptor antagonists, methiothepin 
and ketanserin, improved retention, but the dose needed to improve retention was at least 
10 times greater in 12-month-old P8 mice than in 4-month-old mice, indicating that there 
was a reduction in serotonin receptor activity in the 12-month-old mice. Similar drug studies 
done in the hippocampus of 4- and 12-month-old mice found no age-related change in the 
dose–response curves of serotonin antagonists for improvement of retention (Flood et al., 
1996). Therefore, these results suggest that with increasing age SAMP8 develops a 
dysfunction in septohippocampal functioning which may initially begin with a decrease in 
serotonergic activity that appears to be specific to the septum.  In agreement with this, the 
serotonin uptake inhibition by indeloxazine hydrochloride [(±)-2[(inden-7-
yloxy)methyl]morpholine hydrochloride], a cerebral metabolic enhancer with cerebral 
activating properties (Yamamoto, 1990), potentiated the serotonergic system in SAMP8 mice 
(Yamaguchi et al., 1998). In fact, 5-hydroxytryptamine (5-HT) levels are significantly lower 
in SAMP8 as compared to SAMR1 mice (Qiu et al., 2010). Similar serotonergic deficits have 
been reported in patients with AD, including loss of 5-HT2 receptors in cerebral cortex (Blin 
et al., 1993), 5-HT4 in hippocampus and frontal cortex (Reynolds et al., 1995) and 5-HT6 in 
pyramidal cells (Lorke et al., 2006). 
4.2 Acetylcholine receptors (muscarinic) 
Muscarinic receptors mediate cellular response to the natural ligand acetylcholine (ACh).  
They enjoy widespread tissue distribution and are involved in the control of numerous 
central and peripheral physiological responses, as well as being a major drug target in 
human disease. This family of G protein-coupled receptors consists of five members 
designated M1-M5. Hence, M2 and M4-muscarinic receptors are able to couple to the 
pertusiss-toxin sensitive Gi/o proteins, and M1, M3 and M5-muscarinic receptors couple to 
Gq/11 proteins. However, the muscarinic receptor family can couple to a wide range of 
diverse signaling pathways, mediated or not by G proteins (Caulfield & Birsall, 1998; van 
Koppen & Kaiser, 2003). In the hippocampus of SAMP8 at 12 months, binding of 
[3H]pirenzepine, a M1 muscarinic receptor antagonist, was significantly lower than that in 
SAMR1. However, in the cerebral cortex, binding was higher in SAMP8 than in SAMR1 at 
12 months (Nomura et al., 1997). In addition, SAMP8 mice show decreased release of 
acetylcholine (Qiu et al., 2010). Thus, there is a decreased cortical acetylcholine content in 
SAMP8 (Kitaoka et al., 2010). Moreover, there is a reported effect of dysfunctional teeth on 
age-related changes in the septohippocampal cholinergic system by assessing acetylcholine 
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(ACh) release and choline acetyltransferase (ChAT) activity in the hippocampus of young-
adult and aged SAMP8 mice after removal of their upper molar teeth (molarless condition) 
(Onozuka et al., 2002). In this experimental model, significantly less KCl-evoked ACh 
release was seen in aged molarless SAMP8 mice compared with aged controls, whereas the 
molarless condition had no effect on young mice. In the control groups, the KCl-evoked 
ACh release decreased with aging, but the difference was not statistically significant. 
Moreover, in control mice, ChAT activity was higher in the young-adult group than in the 
aged mice, indicating an age-dependent decrease in hippocampal ChAT activity in SAMP8 
mice. In addition, aged molarless mice showed a greater reduction in ChAT activity than 
age-matched control mice, whereas the molarless condition had little effect on young-adult 
mice (Onozuka et al., 2002). This decreased cholinergic activity results in a decreased ability 
of the SAMP8 mouse to learn and retain new information (Morley et al., 2002). In fact, M1 
mAChR is the most abundant subtype in the cortex and hippocampus, two major brain 
regions that develop amyloid plaques and neurofibrillary tangles (nFTs) in AD, and 
postsynaptic M1 mAChRs play a major role in hippocampus-dependent short-term memory 
and memory consolidation (Anagnostaras et al., 2003), which is impaired in AD (Levey, 
1996). Therefore, considerable efforts have been directed towards developing M1 
mAChR-selective agonists that are capable of restoring the cognitive deficits in patients with 
AD, in whom hippocampus M1 level are reduced (Pakrasi et al., 2007) while they are 
increased in frontal cortex (Svensson et al., 1992). 
4.3 Adenosine receptors 
Adenosine is a nucleoside widely distributed in central and peripheral nervous system that 
exerts its actions through four types of receptors named A1, A2A, A2B and A3, all of them 
being GPCRs. A1 and A3 receptors are coupled, through Gi/o proteins, to adenylyl cyclase 
activity inhibition, while A2A and A2B receptors are coupled to stimulation of the enzymatic 
activity, through Gs protein (Ralevic & Burnstock, 1998; Fredholm et al., 2001, 2005). Out of 
the four adenosine receptors, the A1 subtype is the most abundant and widespread in the 
brain, where it plays a neuroprotective role because of its capacity to decrease the release of 
excitatory neurotransmitters, mainly glutamate (Dunwiddie & Masino, 2001). A2A receptors 
are concentrated in the basal ganglia but they are also present throughout the brain, albeit in 
a considerably lower density. A2B and A3 receptors are the least abundant in the brain 
(Cunha, 2005). Adenosine receptor gene expression and the quantification of A1 and A2A 
proteins in plasma membranes were analyzed recently in SAMP8 and SAMR1 strains using 
21- and 180-day-old animals (Castillo et al., 2009). Results show that mRNA coding 
adenosine A1 and A2B receptors is significantly increased in middle-aged versus young 
SAMR1 animals, suggesting an age-associated up-regulation in resistant control mice. 
However, these increases were not detected in SAMP8 animals. Concerning A2A receptors, 
no significant differences were found between young and middle-aged animals, either in 
SAMP8 or in SAMR1. However, the level of A2A mRNA expression was significantly lower 
in SAMP8 versus SAMR1. Finally, an increase in mRNA coding A3 receptor was observed in 
both middle-aged SAMR1 and SAMP8 animals without significant differences between 
strains. Adenosine A1 receptors were measured in plasma membranes from SAMR1 and 
SAMP8 mice by binding assay using [3H]DPCPX, a selective A1 receptor antagonist, as 
radioligand. Total adenosine A1 receptor numbers in middle-aged SAMR1 decreased by 
38%, suggesting a loss of receptors associated with aging. This decrease was not observed in 
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the SAMP8 strain. However, and of interest, total A1 receptor level in SAMP8 was 
significantly lower than in SAMR1, with even fewer receptors detected than in middle-aged 
SAMR1 mice, suggesting that A1 receptors are already altered at a very early age in SAMP8. 
No significant age-associated differences in Kd values were observed in any SAM strain. 
However, Kd values in SAMP8 strain were lower than in SAMR1, suggesting a higher 
receptor affinity in the former. This age-related loss of A1 receptors in SAMR1 was then 
associated with an increase in the rate of synthesis of this receptor, probably as a 
compensatory mechanism to prevent the important loss of receptor detected at the 
membrane surface. In contrast, an age-related increase in adenosine A2A receptors was 
observed in SAMR1 with no variation in SAMP8, by Western-blotting. The most important 
finding in the paper of Castillo et al. is that adenosine A1 receptors, which have been 
described as being neuroprotective, are already severely decreased in very young SAMP8 
mice (3 weeks old), suggesting a great alteration of these receptors in this aging model. 
Higher A1 and A2A receptor expression levels have been found in the frontal cortex of 
post-mortem brains of patients with AD (Albasanz et al., 2008). Interestingly, A2A-deficient 
mice display improved spatial recognition memory (Wang et al., 2006), whereas in vivo A2A 
overexpression leads to memory deficits (Gimenez-Lort et al., 2007). In agreement, 
pharmacological blockade of A2A receptors by caffeine seems to reduce A formation and 
the risk of developing dementia (Chen & Chern, 2011; Gelber et al., 2011). 
4.4 Adrenergic receptors 
Adrenoceptors are 7-transmembrane receptors which mediate the central and peripheral 
actions of the neurotransmitter noradrenaline (norepinephrine), and the hormone and 
neurotransmitter adrenaline (epinephrine). Adrenoceptors are found in nearly all 
peripheral tissues and on many neuronal populations within the central nervous system. 
Both noradrenaline and adrenaline play important roles in the control of blood pressure, 
myocardial contractile rate and force, airway reactivity, and a variety of metabolic and 
central nervous system functions. Based on both pharmacological and molecular evidence 
they are classified into three major types -┙1, ┙2 and ┚- each of which is further divided 
into at least three subtypes (Bylund et al., 1994). Agonists for norepinephrine receptors 
required little or no change in the dose needed to improve retention in older SAMP8 (12- 
versus 4-month-old) mice on a T-maze footshock avoidance test (Flood et al., 1998), 
suggesting that this signaling pathway is not modified with aging in SAMP8 mice. In 
contrast, the level of total ┚-adrenergic receptors and, more interestingly, the relative ratio 
of ┚1-/┚2-receptors, have been reported as altered in different brain regions from AD 
patients (Kalaria et al., 1989). Thus, there is an increase in ┚2-receptors in prefrontal cortex 
and hippocampus which could be responsible for the amelioration in AD patients 
detected by blocking ┚-adrenergic receptors with selective antagonists (Yu et al., 2011). 
Thus, a similar modulation in SAMP8 mice must not be ruled out as no detailed studies 
have been performed to date. 
4.5 Calcitonin receptors 
The calcitonin peptide family comprises calcitonin, amylin, calcitonin gene-related peptide 
(CGRP), adrenomedullin (AM) and AM2, also known as intermedin. All of these peptides, 
ranging from 32 to 52 amino acids in length in humans, share structural similarities, and 
their truncation beyond the second cysteine residue generates antagonists. With the 
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exception of CGRP receptors, such modified forms of the native peptides are the only 
pharmacological tools currently available for characterizing these receptors. The receptor 
family for these peptides consists of two class B GPCRs, the calcitonin receptor (CR) and 
calcitonin receptor-like receptor (sometimes abbreviated as CRLR) for which 
pharmacological specificity is dictated by additional proteins, known as receptor activity-
modifying proteins (RAMPs). These are integral parts of the receptor complex (Hoare et al., 
2005). In male SAMP8 and SAMR1 mice, blood samples were collected monthly from 3 to 12 
months of age. With advancing age, the plasma calcitonin (CT) levels decreased 
progressively in both SAMR1 and SAMP8. However, the curve of age-related changes in the 
plasma CT levels was lower in SAMP8 than in SAMR1 (Chen et al., 2004).  Measurement of 
CT level in female SAMP8 mice at the age of 3, 6, 9, 12, and 15 months revealed that plasma 
CT level decreased with aging and/or ovariectomy. Plasma CT levels in the ovariectomized 
(Ovx) mice were significantly lower than those in the intact mice. In addition, the decrease 
of plasma CT level was moderated by long-term dietary antler supplementation in both Ovx 
and intact mice (Chen at al., 2007). Although no data were found concerning CT receptors in 
SAMP8 mice, a reduced level of the endogenous agonist (CT) could suggest reduced 
signaling through these receptors. In fact, a possible receptor upregulation could be 
expected in response to low CT levels as a compensatory mechanism. Interestingly, the 
amylin receptor is a putative target for the actions of A┚ in the brain. Thus, in primary 
cultures of human fetal neurons (HFNs), AC253, an amylin receptor antagonist, blocks the 
electrophysiological effects of A┚. Moreover, in transgenic mice (TgCRND8) that 
overexpress amyloid precursor protein, amylin receptor is up-regulated in specific brain 
regions that also demonstrate an elevated amyloid burden (Jhamandas et al., 2011). 
4.6 Chemokine receptors 
Chemokines (chemotactic cytokines) comprise a family of related proteins according to 
structural criteria including overall amino acid sequence homology, length, conserved 
cysteine motifs and a common fold.  They are involved in leukocyte trafficking, 
antimicrobial activity, HIV inhibitory activity, angiogenic or angiostatic activity, tumour-
promoting or tumour-inhibiting activity, apoptosis or mitogenic activity, and the ability to 
modulate gene expression, T cell differentiation and phagocyte activation. Chemokines act 
by binding to 7-transmembrane domain, G protein-coupled receptors. There are 18 human 
chemokine receptors and over fifty distinct chemokines (Melik-Parsadaniantz & Rostene, 
2008). An interesting region has been found on chromosome 4 of SAMP8 mice harboring 
multiple genes that were more highly expressed in SAMP8 than in SAMR1; some of these 
genes are chemokine (C-C motif) ligand 19 (Ccl19) and Ccl27. The RNA levels for these two 
genes in retina or hippocampus were higher in SAMP8 than SAMR1 (Carter et al., 2005). In 
addition, CCL2, a small cytokine belonging to the CC chemokine family that is also known 
as monocyte chemotactic protein-1 (MCP-1), has a significantly increased expression in old 
as compared with young SAMP8 mice, and this expression was significantly reduced after 
melatonin treatment. In SAMR1 mice no statistically significant differences between young 
and old animals were found. CCL2 expression was also elevated in old SAMP8 mice when 
compared with old SAMR1 mice (Cuesta et al., 2010). CCL2 is the main ligand for 
chemokine receptor CCR2, which is required for macrophage infiltration at sites of axonal 
injury in the hippocampus. CCL2 has been localized to mature amyloid plaques in the AD 
brain (Ishizuka et al., 1997). 
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4.7 Dopamine receptors 
Dopamine receptor subtypes are named D1-D5 and belong to two subfamilies, D1-like and 
D2-like, based upon similarities in sequence, pharmacology and ability to stimulate or 
inhibit adenylyl cyclase activity mediated via coupling to G┙s or G┙i/o proteins (Beaulieu & 
Gainetdinov, 2011). Retention improvement by agonists for dopamine receptors was similar 
in older SAMP8 (12- versus 4-month-old) mice on a T-maze footshock avoidance test (Flood 
et al., 1998), suggesting that this signaling pathway is not modified with aging in SAMP8 
mice. However, there is a decrease in the number of dopamine (DA) neurons and the 
associated ultrastructural changes in the neurons of the nigrostriatal system in SAMP8 as 
compared with SAMR1. This reduction is even greater in aged SAMP8 mice (8–10 months 
old) (Karasawa et al., 1997), suggesting a reduced DA level in SAMP8 worsened by age. The 
administration of 2,4-diamino-6-hydroxypyrimidine (DAHP), an inhibitor of GTP 
cyclohydrolase I, to inhibit DA and serotonin syntheses in young mice (2 months old) and 
aged mice (10 months old), revealed that DA turnover is lower in aged mice than in young 
mice (Karasawa et al., 1999). This DA level could be modulated by diet or MPTP 
administration. DA level was similarly and significantly increased in cerebellum at 8 and 12 
months of age after diet restriction (Kim & Choi, 2000). In contrast, administration of MPTP 
can induce a marked decrease in striatal DA levels and a loss of dopaminergic neurons in 
the substantia nigra of SAMP8 mice (Liu et al., 2008). Moreover, old MPTP-SAMP8 mice 
show an earlier and more severe loss of dopaminergic neurons than young mice (Liu et al., 
2010a). No data concerning modulation of dopamine receptors was found for SAMP8 mice. 
However, in frontal cortex from AD brain, expression of D1, D3 and D4 receptors was 
severely reduced, D2 was moderately reduced and D5 was the only receptor subtype whose 
expression was increased in AD (Kumar & Patel, 2007). Also, in temporal lobe of AD brain 
these dopamine receptors have a reduced expression (Gahete et al., 2010). In addition, DA 
plasma level is significantly lower in AD patients (Umegaki et al., 2000). 
4.8 GABAB receptors 
The GABAB receptor is a Gi/Go protein-coupled receptor heterodimer with two subunits, 
designated 1 and 2. Activation at this site produces neuronal hyperpolarization by 
increasing membrane K+ conductance. The antispastic agent (-)-baclofen is a highly selective 
agonist for GABAB receptors (Martin et al., 2001). Saclofen, a GABAB receptor antagonist, 
had to be injected into the septum at a higher dose in 12- than in 4-month-old mice to 
improve retention in SAMP8 mice after training on footshock avoidance (Flood et al., 1998), 
suggesting a possible upregulation of GABAB receptor. However, a quantitative 
autoradiography study of GABAB and GABAA receptors in AD revealed fewer hippocampal 
GABAB receptors in stratum moleculare of the dentate gyrus, stratum lacunosum-
moleculare and stratum pyramidale of CA1 (Chu et al., 1987a), and a significantly lower 
GABAB level in frontal cortex (Chu et al., 1987b), with no significant differences on affinity 
(Kd). Also, the GABA level in cerebrospinal fluid was significantly reduced in AD patients 
(Jimenez-Jimenez et al., 1998). 
4.9 Melatonin receptors 
There are three major plasma membrane receptors for melatonin within the brain. Two of 
these, MT1 and MT2, are GPCRs whose activation leads to decreased levels of cyclic AMP. 
The third, MT3 or NQO2, is a quinone reductase with poorly understood in vivo function 
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(Reppert et al., 1996; Rios et al., 2010; Tan et al., 2007). However, other mechanisms of action 
could be possible as there are additional melatonin binding sites in the nucleus of many cell 
types (Filadelfi & Castrucci, 1996). Melatonin acts as a neurohormone affecting 
transcriptional events in the CNS (Kotler et al., 1998). Several studies have shown that 
melatonin levels are diminished in AD patients compared to age-matched control subjects. 
CSF melatonin levels decrease even in preclinical stages when the patients do not manifest 
any cognitive impairment (at Braak stages I-II), suggesting that the reduction in melatonin is 
an early marker for the first stages of AD (for a review see Cardinalli et al., 2010). MT1 
activation depresses CREB and stimulates ERK (Chan et al., 2002). MT2 levels are depressed 
in AD (Savaskan et al., 2005). Changes in these signaling pathways may form the basis of the 
alteration in gene expression effected by melatonin. The linkage between reduced melatonin 
levels and accelerated aging has been reviewed elsewhere (Bondy & Sharman, 2007) and 
may be more than merely correlative. Levels of both MT1 and MT2 receptors are very high 
within the suprachiasmatic nucleus (SCN), the site of circadian rhythm regulation. 
However, although administration of melatonin in drinking water promotes the phase 
advance of light–dark cycle in senescence-accelerated SAMR1 but not SAMP8 mice, levels of 
expression of both MT1 and MT2 mRNAs in the SCN are identical in the two SAM strains 
(Asai et al., 2000). 
4.10 Opioid receptors 
The opioid peptide receptors are heterogeneous. Measures of antagonist affinities against 
various opioid agonists in different systems resulted in unambiguous evidence for 
heterogeneity of receptor types, and the eventual definition of the μ, ├ and κ receptor types 
(Dawan et al., 1996). In vivo (+)-[3H]SKF-10,047 binding to σ sites was examined in the 
hippocampal formation and cerebral cortex of SAMR1 and SAMP8, at 12 months of age. 
Binding levels expressed as fmol/mg of proteins indicated decreases in the levels of total 
(+)-[3H]SKF-10,047 bound in the cortex of SAMP8 as compared with SAMR1, but not in the 
hippocampus, and in the levels of (+)-[3H]SKF-10,047 non-specifically bound in both 
structures. However, bound-to-free ratios never significantly differed between the two 
substrains. The apparent reductions in the in vivo binding levels of SKF-10,047 tracer may 
thus not reflect decreased binding capacities at the σ sites. However, the learning 
impairment observed in 10- to 12-month-old SAMP8 could be significantly attenuated by 
two high affinity σ agonists, JO-1784 (igmesine) and PRE-084, administered subcutaneously 
in the mg/kg range, on several tests of mnemonic capacities (Maurice et al., 1996). ├-OR 
binding is decreased in the amygdala and ventral putamen, and μ-OR binding is decreased 
in the hippocampus and subiculum of post-mortem brain samples from patients with AD. 
In addition, there is an elevated hippocampal level of enkephalin, the ligand for these 
receptors, in the human AD brain (for a review see Thathiah & De Strooper, 2011). 
4.11 Orexin receptors 
The orexins (orexin-A and orexin-B, also known as hypocretin-1 and hypocretin-2) are 
neuropeptides derived from a single precursor expressed in a few thousand neurons 
restricted to the posterior lateral and medial hypothalamus. Orexin-A is the selective 
endogenous agonist for OX1 receptor, which is coupled to the activation of phospholipase C 
via a Gs/Gq protein (Zhu et al., 2003). Inactivation of the receptor has been shown to cause 
impaired spatial learning in anaesthetized rats (Akbari et al., 2006). The effect of post-
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training intracerebroventricular administration of Orexin-A on retention in active and 
passive avoidance has been reported in young (4 months) and old (12 months) SAMP8 mice 
(Jaeger et al., 2002). Orexin-A improved retention in young and old SAMP8 mice. However, 
no data about orexin receptor levels have been reported to date. Of interest is the 
observation that A┚ produced by neurons and secreted into the brain interstitial fluid is 
modulated by orexin in transgenic (Tg2576) mice, which express a mutated form of human 
amyloid precursor protein (APP) (Kang et al., 2009). Hypocretin-1 levels were normal in AD, 
although fragmentation of daytime wake was elevated in those with low hypocretin-1 
levels. Thus, lower hypocretin-1 levels may be permissive for, or a consequence of, increased 
wake fragmentation in AD (Friedman et al., 2007). 
4.12 Parathyroid hormone receptors 
Parathyroid hormone (PTH), parathyroid hormone-related protein (PTHrP), and 
tuberoinfundibular peptide of thirty-nine residues (TIP39) are endogenous ligands for the 
parathyroid hormone 1 and 2 receptors (PTH1, PTH2). PTH is a classic endocrine hormone 
essential for mineral homeostasis (Potts et al., 1995). With advancing age (3, 6, 9, 12, and 15 
months), the plasma PTH level increased progressively in female SAMP8 (Chen et al., 2007). 
In male SAMP8 and SAMR1 mice blood samples were collected monthly from 3 to 12 
months of age. With advancing age, the plasma PTH level increased progressively in both 
SAMR1 and SAMP8 (Chen at al., 2004). The increase in serum PTH level has also been 
reported in older people and has been associated with impaired cognitive function, 
although the predictive value of PTH for cognitive decline has not yet been fully 
investigated (Bjorkman et al., 2010). 
4.13 Somatostatin receptors 
The somatostatin receptor family consists of 5 subtypes (sst1-5) each differentially 
distributed throughout the CNS and periphery. These receptors bind with high affinity to 
the endogenous polypeptides somatostatin-14, somatostatin-28 and cortistatin, as well as 
many other synthetic ligands. Receptor activation stimulates multiple intracellular signaling 
mechanisms giving rise to many tissue functions such as inhibition of growth hormone (GH) 
release and modulation of neuronal activity (Moller et al., 2003). The protein expression 
profile changes in the frontal cortex brain of SAMP8 model by means of microarray and RT-
PCR techniques has recently been analyzed (Chen at al., 2010). In this study, somatostatin 
gene expression was lower in 12-month-old as compared with 4-month-old SAMP8 mice. 
Interestingly, the administration of NNC 26-9100, an sst4 receptor agonist, to 12-month-old 
SAMP8 mice did not modulate the expression of the sst4 receptor and APP when compared 
to vehicle control mice after 28 days of chronic NNC treatment, but it did enhance learning 
and memory (Sandoval et al., 2011). In addition, the expression of somatostatin did not 
change during aging in the pancreas of male SAMP8 and SAMR1 mice as no significant 
differences were observed between old (10 month) and young (2 month) mice. However, the 
expression of somatostatin was higher in the pancreas of young SAMP8 mice as compared 
with young SAMR1 mice (Cuesta et al., 2011). The expression of sst2 and sst4 is reduced in 
the cortex of human patients with AD (Kumar, 2005). Moreover, somatostatin levels are also 
reduced in the CSF, cortex and hippocampus of patients with AD (Thathiah & De Strooper, 
2011). 
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4.14 Thyrotropin-releasing hormone receptors 
Thyrotropin-releasing hormone (TRH) is a tripeptide (pyroGlu-His-Proamide) that is 
synthesized in the hypothalamus and released into the hypothalamic-pituitary portal 
circulation to act on the pituitary. TRH is produced in many other tissues, especially within 
the nervous system, where it appears to act as a neurotransmitter/neuromodulator. TRH 
receptors (TRH1, TRH2) belong to the Class A GPCR family. TRH2 receptor has not been 
found in humans (Straub et al., 1990). Subcutaneous injection of a sustained release 
formulation of thyrotropin-releasing hormone (TRH-SR) produced a sustained increase in 
immunoreactive plasma TRH levels up to about 4 weeks after dosing in 8-month-old 
SAMP8. Furthermore, TRH-SR significantly improved the impairment of water maze 
learning in SAMP8 mice (Miyamoto et al., 1994a). TRH-SR also ameliorates impairments of 
learning behavior and the emotional disorder in SAMP8. In addition, SAMP8 shows an age-
dependent abnormality of circadian rhythms of spontaneous motor activity (SMA) and 
ingestive behavior compared with the SAMR1 control, with diurnal SMA and water intake 
in SAMP8 being higher than in SAMR1 (Miyamoto, 1994b). These results suggest a reduced 
TRH level in SAMP8 mice. TRH concentration was decreased in the AD hippocampus 
compared to normal elderly controls (Luo et al., 2002). However, no significant differences 
from non-neuropsychiatric controls were noted on TRH receptor levels within the 
hippocampus in AD; just a slight alteration was noted in the cortical amygdala in AD 
(Lexow et al., 1994). 
4.15 PACAP receptors 
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide 
(PACAP) are members of a superfamily of structurally related peptide hormones that 
includes glucagon, glucagon-like peptide, secretin and growth hormone-releasing hormone 
(GHRH). At least three receptors for PACAP exist in mammals, two of which are also high-
affinity receptors for VIP (Harmar et al., 1998). In SAMP88 mice, PACAP is transported 
across the BBB in almost all regions of the brain, with the highest rates of transport found in 
the hypothalamus and hippocampus. This transport is lower in aged (12-month-old) than in 
young (2-month-old) mice. Of the differences between young and aged SAMP8 mice, the 
most interesting is the loss of the ability to transport PACAP into the olfactory bulb (Nonaka 
et al., 2002). Several studies have found abnormalities of the olfactory bulb of both SAMP8 
mice (Ueno et al., 1998) and patients with Alzheimer’s disease (Kovacs et al., 2001). 
4.16 Metabotropic glutamate receptors 
Glutamate is the main excitatory neurotransmitter in the central nervous system which has 
been implicated in several physiological and pathological processes (Conn & Pin, 1997). The 
different actions of glutamate are mediated through glutamate receptor binding, which has 
been classified into ionotropic and metabotropic. Metabotropic glutamate receptors 
(mGluRs) are coupled, through G proteins, to different effector systems, including 
phospholipase C (PLC) and adenylyl cyclase (AC). They have been classified into three 
groups on the basis of their pharmacological profile, molecular properties, and transduction 
mechanisms. Group I receptors (mGlu1, mGlu5) are coupled to PLC activation, through Gq/11 
proteins, whereas groups II and III are coupled to AC inhibition, through Gi/o proteins 
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(Conn & Pin, 1997). Preliminary results by our group suggest that mGluRs are impaired in 
SAMP8 mice (unpublished data). Interestingly, the mGluR/phospholipase C signaling 
pathway is impaired in the cerebral cortex in AD patients. Moreover, a decrease in mGluR 
specific binding correlates well with stage of AD-related changes (Albasanz et al., 2005). The 
efficacy of glutamatergic neurotransmission also relies on glutamate uptake and release 
from vesicles (Ishikawa et al., 2002; Wojcik et al., 2004). Vesicular glutamate transporters 
(VGLUTs), which include VGLUT1, VGLUT2 and VGLUT3, are responsible for the 
uploading of L-glutamate into synaptic vesicles and they are specifically required for 
exocytotic release (Reimer & Edwards, 2004). For glutamatergic synapses, a single functional 
vesicular glutamate transporter is both necessary and sufficient to fill a synaptic vesicle. 
However, elevated VGLUT expression increases the quantal size of a vesicle, and vesicles 
without VGLUT are empty (Daniels et al., 2006). Therefore, the expression level of VGLUTs 
determines the amount of glutamate that is loaded into vesicles and released, and thereby 
regulates the efficacy of neurotransmission (Ishikawa et al., 2002; Wojcik et al., 2004). Protein 
expression of VGLUT1, VGLUT2, VGLUT3 and synaptophysin (Syp), a marker of synapse 
(Kashani et al., 2008), tends to decrease in the hippocampus, and was significantly decreased 
in an age-dependent manner in the cerebral cortex of SAMP8 with age-related deterioration 
of learning and memory (Cheng et al., 2011), which could indicate that the glutamatergic 
synaptic transmission was weakened in the brain of aging SAMP8. Consistent with a 
dysfunction in the recycling of glutamate, there is a selective loss of vesicular glutamate 
transport in synaptic vesicles isolated from cerebral cortex synaptosomes from AD 
(Westphalen et al., 2003). 
 
GPCR AD SAMP8 
5-Hydroxytryptamine 
receptors 
↓ 5-HT2A, 5-HT4, 5-HT6 ↓ serotonergic activity (5-HT1, 
5-HT2) 




↓ hippocampal M1 ↓ hippocampal M1 
 ↑ frontal cortical M1 ↑ cortical M1 
 ↓ ACh release ↓ ACh release 
Adenosine receptors ↑ frontal cortical A1, A2A ↓ A1, ↑ A2A (whole brain) 
Adrenoceptors ↑ prefrontal cortical and 
hippocampal 2AR 
no apparent change 
Calcitonin receptors ↑ amylin receptor (TgCRND8 
mice) 
↓ plasma calcitonin 
Chemokine receptors ↑ CCL2 ↑ hippocampal Ccl19, Ccl27 
expression, ↑ CCL2 
Dopamine receptors ↓ frontal cortical D1, D3, D4, D2 
↑ frontal cortical D5 
↓ temporal lobe DR 
n.d. 
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GPCR AD SAMP8 
 ↓ DA level ↓ DA level 
GABAB receptors ↓ hippocampal and cortical 
GABAB 
n.d. 
 ↓ GABA level in CSF n.d. 
Melatonin receptors ↓ MT2 = MT1, MT2 mRNA 
expression 
 ↓ melatonin level in CSF n.d. 
Opioid receptors ↓ ├-OR amygdala and putamen 
↓ μ-OR hippocampus and 
subiculum 
↓ cortical  site 
= hippocampal  site 
 ↑ hippocampal enkephalin n.d. 
Orexin receptors = Hypocretin-1 level n.d. 
Parathyroid hormone 
receptors 
= PTH level (but ↑ PTH with 
aging) 
↑ PTH level with aging 
Somatostatin 
receptors 
↓ sst2, sst4 n.d. 
 ↓ somatostatin level ↓ somatostatin level 
Thyrotropin-releasing 
hormone receptors 
= hippocampal TRH receptors 
↓ cortical amygdala TRH 
receptor 
n.d. 
 ↓ TRH level ↓ TRH level 




↓ mGluR in frontal cortex not published 
 ↓ VGLUT ↓ VGLUT 
 
Table 3. G protein-coupled receptors assessed in Alzheimer's disease (AD) and senescence-
accelerated mouse P8 strain (SAMP8). n.d.: not determined. GPCRs that have been not 
investigated in SAMP8, or at least not found in literature, are the following: Anaphylatoxin, 
Angiotensin, Apelin, Bile acid, Bombesin, Bradykinin, Calcium-sensing, Cannabinoid, 
Cholecystokinin, Corticotropin-releasing factor, Endothelin, Estrogen (G protein-coupled) 
Formylpeptide, Free fatty acid, Frizzled, Galanin, Ghrelin, Glucagon receptor family, 
Glycoprotein hormone, Gonadotrophin-releasing hormone, Histamine, Hydroxycarboxylic 
acid, Kisspeptin, Leukotriene, Lysophospholipid, Melanin-concentrating hormone, 
Melanocortin, Motilin, Neuromedin U, Neuropeptide FF/neuropeptide AF, Neuropeptide S 
receptor, Neuropeptide W/neuropeptide B, Neuropeptide Y, Neurotensin, P2Y, Peptide 
P518, Platelet-activating factor, Prokineticin, Prolactin-releasing peptide, Prostanoid, 
Protease-activated, Relaxin family peptide, Tachykinin, Trace amine, Urotensin and 
Vasopressin and oxytocin receptors. 
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5. Conclusion 
Senescence-accelerated mouse P8 (SAMP8) has many features that are known to occur early 
in the pathogenesis of AD such as increased oxidative stress, amyloid-┚ alterations, and tau 
phosphorylation. The neurochemical changes reported to date in SAMP8 mice may help in 
the study of AD pathogenesis as many of them are similar to what is found in AD (see Table 
3). However, there is still a lot of work to be done in the analysis of the different receptor-
mediated signaling pathways and their modulation in this animal model. 
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